To quantify the benefit of hepatitis C virus treatments to society, including the value of reduced transmission, Van Nuys, Brookmeyer, Chou, Goldman, and colleagues estimated the effects of several hepatitis C treatment strategies on cost and population health. Treating patients at all disease stages could generate $610–$1,221 billion in additional quality-adjusted life-years, plus an additional $139 billion in saved medical expenditures over 50 years, and minimize the disease burden, but up-front treatment costs would exceed $150 billion. An intermediate scenario—treating 5 percent of the infected population annually, regardless of patients’ disease stages—would also return substantial benefits and would be much more affordable under current financing schemes.
Citation: Van Nuys, K., Brookmeyer, R., Chou, J. W., Dreyfus, D., Dieterich, D., & Goldman, D. P. (2015). Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, but Capacity Is a Concern. Health Affairs.